Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 3, 2003, Pages 853-863

  Ciernik, I Frank ^a   Dizendorf, Elena ^a   Baumert, Brigitta G ^a,b   Reiner, Beatrice ^a   Burger, Cyrill ^a   Davis, J Bernard ^a   Lütolf, Urs M ^a   Steinert, Hans C ^a   Von Schulthess, Gustav K ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Combined PET CT; FDG PET; GTV; Hybrid PET CT; Integrated CT PET; PET CT; PTV; Radiation oncology; Radiotherapy; Radiotherapy planning; Target volume; Volume delineation

Indexed keywords

COMPUTERIZED TOMOGRAPHY; DOSIMETRY; IONIZING RADIATION; MEDICAL IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY; TUMORS;

TREATMENT PLANNING;

ONCOLOGY;

FLUORODEOXYGLUCOSE F 18;

ACCURACY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GEOGRAPHY; HEAD AND NECK CANCER; HUMAN; IMAGING; IONIZING RADIATION; LUNG CANCER; MALE; METABOLISM; METASTASIS; ONCOLOGY; PALLIATIVE THERAPY; PELVIS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0141615676     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00346-8     Document Type: Article

References (41)

1. Rosenman J. Incorporating functional imaging information into radiation treatment. Semin Radiat Oncol. 11:2001;83-92.
2. Dwamena B.A., Sonnad S.S., Angobaldo J.O., et al. Metastases from non-small cell lung cancer Mediastinal staging in the 1990s - meta-analytic comparison of PET and CT . Radiology. 213:1999;530-536.
3. Gupta N.C., Tamim W.J., Graeber G.G., et al. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest. 120:2001;521-527.
4. Hawighorst H., Knapstein P.G., Weikel W., et al. [Invasive cervix carcinoma (pT2b-pT4a). Value of conventional and pharmacokinetic magnetic resonance tomography (MRI) in comparison with extensive cross sections and histopathologic findings]. Radiologe. 37:1997;130-138.
5. Maier A.G., Kersting-Sommerhoff B., Reeders J.W., et al. Staging of rectal cancer by double-contrast MR imaging using the rectally administered superparamagnetic iron oxide contrast agent ferristene and IV gadodiamide injection Results of a multicenter phase II trial . J Magn Reson Imaging. 12:2000;651-660.
6. Block M.I., Patterson G.A., Sundaresan R.S., et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg. 64:1997;770-777.
7. Czernin J., Phelps M.E. Positron emission tomography scanning Current and future applications . Annu Rev Med. 53:2002;89-112.
8. Weder W, Schmid RA, Bruchhaus H, et al. Detection of extrathoracic metastases by position emission tomography in lung cancer. Ann Thorac Surg 1998;66:886-883.
9. Dizendorf E., Baumert B.G., Von Schulthess G.K., et al. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation oncology. J Nucl Med. 44:2003;24-29.
10. Brizel D.M. Future directions in toxicity prevention. Semin Radiat Oncol. 8:1998;17-20.
11. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas First report of RTOG 9003 . Int J Radiat Oncol Biol Phys. 48:2000;7-16.
12. Kessler M.L., Pitluck S., Petti P., et al. Integration of multimodality imaging data for radiotherapy treatment planning. Int J Radiat Oncol Biol Phys. 21:1991;1653-1667.
13. Hamilton R.J., Sweeney P.J., Pelizzari C.A., et al. Functional imaging in treatment planning of brain lesions. Int J Radiat Oncol Biol Phys. 37:1997;181-188.
14. Gross M.W., Weber W.A., Feldmann H.J., et al. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys. 41:1998;989-995.
15. Rahn A.N., Baum R.P., Adamietz I.A., et al. [Value of 18F fluorodeoxyglucose positron emission tomography in radiotherapy planning of head-neck tumors]. Strahlenther Onkol. 174:1998;358-364.
16. Kiffer J.D., Berlangieri S.U., Scott A.M., et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer. 19:1998;167-177.
17. Nuutinen J., Sonninen P., Lehikoinen P., et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys. 48:2000;43-52.
18. Giraud P., Grahek D., Montravers F., et al. CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys. 49:2001;1249-1257.
19. Erdi A.K., Erdi Y.E., Yorke E.D., et al. Treatment planning for radio-immunotherapy. Phys Med Biol. 41:1996;2009-2026.
20. Mah K., Caldwell C.B., Ung Y.C., et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma A prospective study . Int J Radiat Oncol Biol Phys. 52:2002;339-350.
21. Burger C., Goerres G., Schoenes S., et al. PET attenuation coefficients from CT images Experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients . Eur J Nucl Med. 29:2002;922-927.
22. ICRU report 62. Prescribing, recording, and reporting photon beam therapy. (Suppl. to ICRU report 50) Bethesda, MD: The International Commission on Radiation Units and Measurements; 1999.
23. Glatstein E., Lichter A.S., Fraass B.A., et al. The imaging revolution and radiation oncology Use of CT, ultrasound, and NMR for localization, treatment planning and treatment delivery . Int J Radiat Oncol Biol Phys. 11:1985;299-314.
24. Ling C.C., Humm J., Larson S., et al. Towards multidimensional radiotherapy (MD-CRT) Biological imaging and biological conformality . Int J Radiat Oncol Biol Phys. 47:2000;551-560.
25. Chapman J.D., Bradley J.D., Eary J.F., et al. Molecular (functional) imaging for radiotherapy applications An RTOG symposium . Int J Radiat Oncol Biol Phys. 55:2003;294-301.
26. Mac Manus M.P., Hicks R.J., Ball D.L., et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma Powerful correlation with survival and high impact on treatment . Cancer. 92:2001;886-895.
27. Munley M.T., Marks L.B., Scarfone C., et al. Multimodality nuclear medicine imaging in three-dimensional radiation treat ment planning for lung cancer Challenges and prospects . Lung Cancer. 23:1999;105-114.
28. Nestle U., Walter K., Schmidt S., et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer High impact in patients with atelectasis . Int J Radiat Oncol Biol Phys. 44:1999;593-597.
29. Erdi Y.E., Rosenzweig K., Erdi A.K., et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol. 62:2002;51-60.
30. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G., et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 55:2000;317-324.
31. Rege S., Maass A., Chaiken L., et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer. 73:1994;3047-3058.
32. Adams S., Baum R.P., Stuckensen T., et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med. 25:1998;1255-1260.
33. Benchaou M., Lehmann W., Slosman D.O., et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol. 116:1996;332-335.
34. Schechter N.R., Gillenwater A.M., Byers R.M., et al. Can positron emission tomography improve the quality of care for head-and-neck cancer patients? Int J Radiat Oncol Biol Phys. 51:2001;4-9.
35. Nishioka T., Shiga T., Shirato H., et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys. 53:2002;1051-1057.
36. Abdel-Nabi H., Doerr R.J., Lamonica D.M., et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET Correlation with histopathologic and CT findings . Radiology. 206:1998;755-760.
37. Yu J.N., Fahey F.H., Gage H.D., et al. Intermodality, retrospective image registration in the thorax. J Nucl Med. 36:1995;2333-2338.
38. Hicks R.J., Mac Manus M.P. 18F-FDG PET in candidates for radiation therapy Is it important and how do we validate its impact? J Nucl Med. 44:2003;30-32.
39. Valley J.F., Mirimanoff R.O. Comparison of treatment techniques for lung cancer. Radiother Oncol. 28:1993;168-173.
40. Caldwell C.B., Mah K., Ung Y.C., et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT The impact of 18FDG-hybrid PET fusion . Int J Radiat Oncol Biol Phys. 51:2001;923-931.
41. Giraud P., Elles S., Helfre S., et al. Conformal radiotherapy for lung cancer Different delineation of the gross tumor volume (GTV) by radiologists and radiation oncologists . Radiother Oncol. 62:2002;27-36.